"...Having obtained U.S. FDA 510(k) Class II approval for its iTBra technology, CI has conducted clinical trials in the U.S. with its newly developed scalable product, which demonstrates greatly improved outcomes, beyond historical product results." http://www.prweb.com/releases/2017/04/prweb14273437.htm